biostudies-literatureLarsen LHelen &amp; Ejnar Bjørnows foundationAugustinus FoundationFoundation for "Lægevidenskabens Fremme"Juchum foundationUniversity of Southern DenmarkAase &amp; Ejnar Danielsen foundationRegion of Southern Denmark's PhD foundationOdense University HospitalGrosserer L. F. Foghts foundation1091https://www.ebi.ac.uk/biostudies/studies/S-EPMC9323946biostudies-literatureUnknown10(7)<h4>Background</h4>Pneumococcal prime-boost vaccination is recommended for solid organ transplant recipients and candidates. The long-term durability of the antibody (AB) response is unknown. The same applies to a dose-dependent immune response.<h4>Methods</h4>We studied the durability of the vaccine response after 18 months in kidney transplant recipients (KTRs) and patients on the kidney transplant waiting list (WLPs). Both groups received either a normal dose (ND) or a double dose (DD) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine. The average pneumococcal AB geometric mean concentration (GMC) was evaluated. A level ≥ 1 mg/L was considered protective against invasive pneumococcal disease (IPD).<h4>Results</h4>Sixty WLPs and 70 KTRs were included. The proportion of participants protected declined from 52% to 33% in WLPs and from 29% to 16% in KTRs, with the previously significant dose-effect in WLPs no longer present (40% DD vs. 27% ND; <i>p</i> = 0.273). Average pneumococcal AB GMCs remained significantly above baseline levels (all groups <i>p</i> ≤ 0.001). Drug-induced immunosuppression diminished the vaccine dose-effect.<h4>Conclusions</h4>At follow-up, the pneumococcal prime-boost vaccination still provided significantly elevated average pneumococcal AB GMCs in both populations. Though the proportion of participants protected against IPD in WLP-DD and WLP-ND were statistically comparable, a DD may still be recommended for WLPs (EudraCT: 2016-004123-23).VaccinesDurability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial.PMC93239460412116-2123459921.262A139917-018510-001896-SDUSF-2016-131Johansen ISBoesby LBistrup CJorgensen CSNielsen CLarsen LSorensen SSfalseDurability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial.<h4>Background</h4>Pneumococcal prime-boost vaccination is recommended for solid organ transplant recipients and candidates. The long-term durability of the antibody (AB) response is unknown. The same applies to a dose-dependent immune response.<h4>Methods</h4>We studied the durability of the vaccine response after 18 months in kidney transplant recipients (KTRs) and patients on the kidney transplant waiting list (WLPs). Both groups received either a normal dose (ND) or a double dose (DD) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine. The average pneumococcal AB geometric mean concentration (GMC) was evaluated. A level ≥ 1 mg/L was considered protective against invasive pneumococcal disease (IPD).<h4>Results</h4>Sixty WLPs and 70 KTRs were included. The proportion of participants protected declined from 52% to 33% in WLPs and from 29% to 16% in KTRs, with the previously significant dose-effect in WLPs no longer present (40% DD vs. 27% ND; <i>p</i> = 0.273). Average pneumococcal AB GMCs remained significantly above baseline levels (all groups <i>p</i> ≤ 0.001). Drug-induced immunosuppression diminished the vaccine dose-effect.<h4>Conclusions</h4>At follow-up, the pneumococcal prime-boost vaccination still provided significantly elevated average pneumococcal AB GMCs in both populations. Though the proportion of participants protected against IPD in WLP-DD and WLP-ND were statistically comparable, a DD may still be recommended for WLPs (EudraCT: 2016-004123-23).2022-01-01T00:00:00Z2022 Jul2024-11-09T18:52:35.768Z2022-08-07T08:12:52.034ZS-EPMC93239463589125510.3390/vaccines10071091